Founded in 2008, Stemcentrx combines state-of-the-art research and GMP manufacturing capabilities. This has allowed us to advance from target discovery in our laboratory to treating patients in clinical trials at an accelerated pace. We are investigating many of the largest and most lethal cancers through our proprietary platforms that identify cancer stem cells and discover novel targets,and we engineer and manufacture antibodies and antibody drug conjugates for those targets.
Stemcentrx has five investigational drugs in human clinical trials. As single agents, three have generated objective clinical responses in patients with small cell lung cancer, triple-negative breast cancer, ovarian cancer, and peritoneal cancer, and two have recently begun phase I clinical trials. Beyond these five clinical programs, we have a pipeline of additional novel targets to address other major cancer types.
On April 28, 2016 Stemcentrx was acquired by AbbVie for $5.8 billion.